1Cameron J. Lupus nephritis. J Am Soc Nephrol, 1999,10:413.
2Cervera R, Khamashta M, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: acom parison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore), 2003,82: 299.
3Hill G, Delahousse M, Nochy D, et al. Outcome of relapse in lupus nephritis: roles of reversal of renal fibrosis and response of inflammation to therapy. Kidney Int,2002,61:2176.
4Petri M, Kasitanon N, Singh S, et al. Systemic Lupus International Collaborating Clinics Renal Activity/Response Exercise Comparison of Agreement in Rating Renal Response. Arthritis Rheum, 2008,58 :1789.
5Petri M, Barr S, Buyon J, et al. RIFLE: Responder Index for Lupus Erythematosus.. Arthritis Rheum, 2000,43 : S244.
6Burt R, Traynor A, Statkute L, et al. Nonmyeloablative Hematopoietic Stem Cell Transplantation for Systemic Lupus Erythematosus. JAMA, 2006,295 : 527.
7Weening J, DAgati V, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematousus revisited. Kidney Int, 2004,65 : 521.
8Gourley MF, Austin HA, 3rd, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med, 1996,125 : 549.
9Boumpas DT, Austin HA, 3rd, Vaughn EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyelophosphamide in severe lupus nephritis. Lancet, 1992, 340: 741.
10Wang HY, Cui TG, Hou FF, et al. Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study. Lupus, 2008,17: 638.
5Tyndall A, Grotwohl A. Immune ablation and stem-cell therapy in autoimmune disease clinical experience. Arthritis Res, 2000, 2: 276-280.
6Bombradier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI, a disease activity index for lupus patients. Arthritis Rheum, 1992, 35: 630-640.
7Flson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum, 1993, 36: 729-740.
8Prevoo ML, Van′t Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum, 1995, 38: 44-48.
9Leng XM, Zhao Y, Zhou DB, et al. Study of treatment of refractory rheumatoid arthritis with autologous peripheral blood stem cell transplantation. Natl Med J China, 2002, 82: 748-751.冷晓梅,赵岩,周道斌,等. 自体外周血干细
10Adachi Y, Inaba M, Amoh Y, et al. Effect of bone marrow transplantation on antiphospholipid antibody syndrome in murine lupus mice. Immunobiology, 1995, 192: 218-230.
2Koneru S, Kocharla L, Higgins GC, et al. Adherence to medications in systemic lupus erythematosus [J]. Clin Rheumatol, 2008, 14 (4): 195-201.
3Ogawa H, Kameda H, Nagasawa H, et al. Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritis [J]. Mod Rheumatol, 2007, 17(2): 92-108.
4Silva-FemdezL, Andreu-Schez JL, Ginzler EM. Current therapy of lu- pus nephritis -Which is the best option? [J]. Rev Clin Esp,2008, 208 (3): 138-141.
6Moore RA, Derry S. Systematic review and mete-analysis of randomized trials and cohort studies of mycophenolate mofetil in lupus nephritis[J]. Arthritis Res Ther, 2006, 8(6): 182.
7Green S Watanade K, Braatz-Trulon J. Inhition of dihydroorotate dehydrogrogenase by the immunosuppressine agent leflunnomide [J]. Biochem pharmacol, 1995, 50(6):861.
8Mana S K, Aggarwall B B. Immunosuppresive leflunnomide metabolite (A771726) blocks TNF-dependent nuelfactor-Kappa B activation and gene expression[J]. J lmmunol, 1999, 162(4 ) : 2095.
9Pagnoux C, Korach J, Guillevin L. Indications of plasma exchange in systemic lupus erythematosus in 2005[J]. Lupus, 2005, 14:871.